Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcjo.2017.09.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Lipoprotein-associated phospholipase A (Lp-PLA): Relevant biomarker and therapeutic target?].
Ann Pharm Fr
January 2025
Service de biochimie métabolique, hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix, AP-HP, 47-83, boulevard de l'Hôpital, 75651 Paris, France; Inserm, CNRS, UFR de pharmacie, UTCBS, université Paris Cité, Paris, France. Electronic address:
Over the last fifteen years, numerous studies have sought to decipher the role of lipoprotein-associated phospholipase A (Lp-PLA) in vascular inflammation-related diseases, notably atherosclerosis. Despite the disappointing results of clinical trials using the Lp-PLA inhibitor darapladib, new pathophysiological, epidemiological and genetic data have enabled the development of new inhibitors. Recent studies also show that Lp-PLA is involved in vascular inflammation-related diseases other than atherosclerosis (ischemic stroke, Alzheimer's disease and vascular dementia, diabetes, cancers…), and inhibition of Lp-PLA could have beneficial therapeutic in these diseases.
View Article and Find Full Text PDF[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
Bull Cancer
January 2025
IUCT Oncopôle Toulouse, service d'urologie, Toulouse, France; Clinique La Croix du Sud, UROSUD, Toulouse, France.
Castration-resistant metastatic prostate cancer remains lethal and a therapeutic challenge. Current strategies are geared towards the personalization of treatments based on the identification of relevant molecular targets, including genomic alterations involved in tumoral processes. Among these novel targeted therapies, poly-ADP-ribose polymerase inhibitors (PARPi), by blocking the action of enzymes involved in deoxyribonucleic acid (DNA) repair, induce the destruction of cells carrying defects in homologous recombination repair, often associated with alterations in genes involved in this mechanism.
View Article and Find Full Text PDF[The circulating PD-L1: An emerging predictive biomarker for immune checkpoint inhibitors response].
Bull Cancer
April 2024
Service d'oncologie médicale, CHU Gabriel-Montpied, 63000 Clermont-Ferrand, France. Electronic address:
Immune checkpoint inhibitors (ICI) have recently become the standard of care for many metastatic solid tumors, with considerable improvements in patient prognosis. However, a non-negligible proportion of patients does not respond to this type of treatment, making it essential to identify predictive factors of this response in order to better adapt the therapy. Among the biomarkers that have been most extensively studied in recent years, tumor PD-L1 levels come out on top, with controversial results for predicting response to ICI.
View Article and Find Full Text PDFUne approche d'affirmation pour les soins aux jeunes transgenres et de diverses identités de genre.
Paediatr Child Health
November 2023
Société canadienne de pédiatrie, comité de la santé de l'adolescent, Ottawa (Ontario)Canada.
Un nombre croissant de jeunes s'identifient comme transgenres ou de diverses identités de genre. De nombreux pédiatres et dispensateurs de soins de première ligne accueilleront cette population dans leur pratique, dans le cadre de soins liés au genre ou de soins de santé généraux. Le présent document de principes se veut une ressource pour orienter les pédiatres et les dispensateurs de soins de première ligne à adopter une approche d'affirmation pour la prestation des soins réguliers à tous les jeunes.
View Article and Find Full Text PDF[SGLT2 inhibitors : on the borders of diabetology, cardiology, nephrology and… primary care].
Rev Med Liege
September 2023
Département de Médecine Générale, ULiège, Belgique.
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is or gliflozins) are now considered as a therapeutic breakthrough in clinical practice, not only for the management of type 2 diabetes (T2D), but also for the treatment of heart failure and chronic renal disease. Patients with T2D are exposed to a higher risk of atheromatic lesions, heart failure and renal insufficiency, all complications that can be reduced by a gliflozin as shown in several placebo- controlled randomised trials in at high risk patients. Unexpectedly, such cardio-renal protection has also been observed among non-diabetic patients with heart failure (both with reduced and preserved ejection fraction) or with chronic kidney disease (especially with albuminuria).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!